Skip header and navigation

Refine By

1530 records – page 1 of 153.

1H-NMR metabolomic biomarkers of poor outcome after hemorrhagic shock are absent in hibernators.

https://arctichealth.org/en/permalink/ahliterature267428
Source
PLoS One. 2014;9(9):e107493
Publication Type
Article
Date
2014
Author
Lori K Bogren
Carl J Murphy
Erin L Johnston
Neeraj Sinha
Natalie J Serkova
Kelly L Drew
Source
PLoS One. 2014;9(9):e107493
Date
2014
Language
English
Publication Type
Article
Keywords
Animals
Biological Markers - blood
Hibernation
Lipids - blood
Magnetic Resonance Spectroscopy
Male
Metabolome
Rats, Sprague-Dawley
Reperfusion Injury - blood - prevention & control
Sciuridae
Shock, Hemorrhagic - blood - therapy
Treatment Outcome
Abstract
Hemorrhagic shock (HS) following trauma is a leading cause of death among persons under the age of 40. During HS the body undergoes systemic warm ischemia followed by reperfusion during medical intervention. Ischemia/reperfusion (I/R) results in a disruption of cellular metabolic processes that ultimately lead to tissue and organ dysfunction or failure. Resistance to I/R injury is a characteristic of hibernating mammals. The present study sought to identify circulating metabolites in the rat as biomarkers for metabolic alterations associated with poor outcome after HS. Arctic ground squirrels (AGS), a hibernating species that resists I/R injury independent of decreased body temperature (warm I/R), was used as a negative control.
Male Sprague-Dawley rats and AGS were subject to HS by withdrawing blood to a mean arterial pressure (MAP) of 35 mmHg and maintaining the low MAP for 20 min before reperfusing with Ringers. The animals' temperature was maintained at 37 ? 0.5 ?C for the duration of the experiment. Plasma samples were taken immediately before hemorrhage and three hours after reperfusion. Hydrophilic and lipid metabolites from plasma were then analyzed via 1H-NMR from unprocessed plasma and lipid extracts, respectively. Rats, susceptible to I/R injury, had a qualitative shift in their hydrophilic metabolic fingerprint including differential activation of glucose and anaerobic metabolism and had alterations in several metabolites during I/R indicative of metabolic adjustments and organ damage. In contrast, I/R injury resistant AGS, regardless of season or body temperature, maintained a stable metabolic homeostasis revealed by a qualitative 1H-NMR metabolic profile with few changes in quantified metabolites during HS-induced global I/R.
An increase in circulating metabolites indicative of anaerobic metabolism and activation of glycolytic pathways is associated with poor prognosis after HS in rats. These same biomarkers are absent in AGS after HS with warm I/R.
Notes
Cites: Am J Physiol Regul Integr Comp Physiol. 2010 Feb;298(2):R329-4019923364
Cites: Gerontology. 2010;56(2):220-3019602865
Cites: Am J Physiol Regul Integr Comp Physiol. 2011 Nov;301(5):R1440-5221865542
Cites: Transplantation. 2011 Dec 15;92(11):1215-2122082817
Cites: Am J Respir Crit Care Med. 2011 Sep 15;184(6):647-5521680948
Cites: Pharmacol Ther. 2012 Feb;133(2):230-5522138603
Cites: Bioanalysis. 2012 Feb;4(3):321-4122303835
Cites: Resuscitation. 2012 Feb;83(2):253-821864484
Cites: Comp Biochem Physiol B Biochem Mol Biol. 2012 May;162(1-3):1-922326449
Cites: Nucleic Acids Res. 2012 Jul;40(Web Server issue):W127-3322553367
Cites: Physiol Genomics. 2012 Jul 15;44(14):717-2722643061
Cites: Resuscitation. 2012 Sep;83(9):1166-7222353638
Cites: Exp Biol Med (Maywood). 2013 May;238(5):539-4823856905
Cites: J Surg Res. 2014 Jan;186(1):338-4524124975
Cites: PLoS One. 2014;9(4):e9422524728042
Cites: Jpn J Pharmacol. 2001 Oct;87(2):143-5011700013
Cites: Am J Surg. 2001 Nov;182(5):481-511754855
Cites: J Comp Physiol B. 2010 Apr;180(4):599-61719967378
Cites: J Trauma. 2010 Jul;69(1):31-4020622576
Cites: J Surg Res. 2010 Nov;164(1):e131-920855081
Cites: Shock. 2010 Dec;34(6):565-7220386494
Cites: Comp Biochem Physiol Part D Genomics Proteomics. 2010 Dec;5(4):265-7320728417
Cites: Am J Physiol Lung Cell Mol Physiol. 2011 Jan;300(1):L4-L1120889676
Cites: J Exp Biol. 2011 Apr 15;214(Pt 8):1300-621430207
Cites: Physiol Genomics. 2011 Jul 14;43(13):799-80721540299
Cites: PLoS One. 2011;6(10):e2702122046435
Cites: Jpn J Pharmacol. 2002 May;89(1):36-4312083741
Cites: Horm Behav. 2003 Feb;43(2):318-2612694642
Cites: J Emerg Med. 2003 May;24(4):413-2212745044
Cites: Surgery. 2003 Aug;134(2):267-7412947328
Cites: Biol Reprod. 1988 Apr;38(3):616-223378074
Cites: J Comp Physiol B. 1988;158(1):25-373385059
Cites: Science. 1989 Jun 30;244(4912):1593-52740905
Cites: J Lipid Res. 1993 Jun;34(6):1009-198354948
Cites: J Cereb Blood Flow Metab. 1994 Mar;14(2):193-2058113316
Cites: Anal Chem. 1995 Mar 1;67(5):793-8117762816
Cites: J Cereb Blood Flow Metab. 1998 Feb;18(2):168-759469159
Cites: Kidney Int. 2005 Mar;67(3):1142-5115698456
Cites: Physiol Rev. 2003 Oct;83(4):1153-8114506303
Cites: Annu Rev Physiol. 2004;66:239-7414977403
Cites: Am J Physiol Gastrointest Liver Physiol. 2005 Mar;288(3):G473-8015701622
Cites: Chem Res Toxicol. 2005 Apr;18(4):639-5415833024
Cites: Annu Rev Nutr. 2005;25:469-9716011475
Cites: Anesth Analg. 2005 Dec;101(6):1577-8316301222
Cites: J Hepatol. 2006 May;44(5):956-6216223541
Cites: Stroke. 2006 May;37(5):1261-516574920
Cites: Surgery. 2006 Sep;140(3):404-1216934602
Cites: Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G895-90116751173
Cites: J Surg Res. 2007 Jan;137(1):96-10217064732
Cites: JPEN J Parenter Enteral Nutr. 2007 Mar-Apr;31(2):94-10017308249
Cites: Bioessays. 2007 May;29(5):431-4017450592
Cites: Acta Cardiol. 2007 Aug;62(4):381-917824299
Cites: Physiol Genomics. 2007 Sep 19;31(1):15-2417536023
Cites: J Cereb Blood Flow Metab. 2008 Jul;28(7):1307-1918398417
Cites: J Neural Transm (Vienna). 2008 Jul;115(7):1011-718478178
Cites: Am J Physiol Regul Integr Comp Physiol. 2008 Jul;295(1):R316-2818434441
Cites: Allergol Int. 2008 Sep;57(3):211-718566550
Cites: Crit Care. 2008;12(4):21818638356
Cites: Shock. 2009 Jan;31(1):40-918497709
Cites: Am J Physiol Regul Integr Comp Physiol. 2009 Feb;296(2):R383-9319052316
Cites: Conf Proc IEEE Eng Med Biol Soc. 2008;2008:4891-419163813
Cites: Brain Res Rev. 2009 Mar;59(2):293-31518845187
Cites: Nucleic Acids Res. 2009 Jul;37(Web Server issue):W652-6019429898
Cites: J Neurochem. 2009 Aug;110(4):1170-919493168
Cites: Exp Biol Med (Maywood). 2009 Sep;234(9):1011-919546346
Cites: Mol Biosyst. 2010 Jan;6(1):215-2420024083
PubMed ID
25211248 View in PubMed
Less detail

2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus.

https://arctichealth.org/en/permalink/ahliterature121853
Source
Cardiovasc Diabetol. 2012;11:93
Publication Type
Article
Date
2012
Author
Loghman Henareh
Stefan Agewall
Author Affiliation
Department of Cardiology Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. loghman.henareh@karolinska.se
Source
Cardiovasc Diabetol. 2012;11:93
Date
2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Angina, Unstable - blood - epidemiology - mortality
Biological Markers - blood
Blood Glucose - metabolism
Chi-Square Distribution
Female
Glucose Tolerance Test
Humans
Incidence
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction - blood - epidemiology - mortality
Predictive value of tests
Prognosis
Proportional Hazards Models
Prospective Studies
Recurrence
Risk assessment
Risk factors
Smoking - adverse effects - epidemiology
Stroke - blood - epidemiology - mortality
Sweden - epidemiology
Time Factors
Abstract
The incidence of cardiovascular events remains high in patients with myocardial infarction (MI) despite advances in current therapies. New and better methods for identifying patients at high risk of recurrent cardiovascular (CV) events are needed. This study aimed to analyze the predictive value of an oral glucose tolerance test (OGTT) in patients with acute myocardial infarction without known diabetes mellitus (DM).
The prospective cohort study consisted of 123 men and women aged between 31-80 years who had suffered a previous MI 3-12 months before the examinations. The exclusion criteria were known diabetes mellitus. Patients were followed up over 6.03???1.36 years for CV death, recurrent MI, stroke and unstable angina pectoris. A standard OGTT was performed at baseline.
2-h plasma glucose (HR, 1.27, 95% CI, 1.00 to 1.62; P?
Notes
Cites: N Engl J Med. 2000 Jan 20;342(3):145-5310639539
Cites: Cardiovasc Diabetol. 2012;11:2122397368
Cites: Am J Med. 2000 Nov;109(7):538-4211063954
Cites: J Clin Invest. 2001 Aug;108(4):635-611518739
Cites: Diabetologia. 2001 Sep;44 Suppl 2:S54-6411587051
Cites: Circulation. 2001 Nov 27;104(22):2673-811723017
Cites: Diabetes Care. 2001 Dec;24(12):2043-811723080
Cites: BMJ. 2002 Jan 12;324(7329):71-8611786451
Cites: Dtsch Med Wochenschr. 2002 May 3;127(18):953-711987015
Cites: Eur Heart J. 2002 Aug;23(16):1267-7512175663
Cites: Diabetes Care. 2002 Oct;25(10):1845-5012351489
Cites: Int J Cardiol. 2004 Oct;97(1):21-415336801
Cites: Eur Heart J. 1985 Mar;6(3):199-2262863148
Cites: J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-672698218
Cites: Am J Hypertens. 1994 Jul;7(7 Pt 1):615-227946163
Cites: Lancet. 1994 Nov 19;344(8934):1383-97968073
Cites: BMJ. 1995 Mar 4;310(6979):555-97888928
Cites: Diabetes Care. 1996 Mar;19(3):257-678742574
Cites: Diabetologia. 1996 Dec;39(12):1577-838960845
Cites: Diabetes Care. 1998 Sep;21(9):1529-339727904
Cites: Circ Res. 1999 Mar 19;84(5):489-9710082470
Cites: Diabetes Care. 1999 Jun;22(6):920-410372242
Cites: J Am Coll Cardiol. 1999 Jul;34(1):146-5410400004
Cites: Lancet. 1999 Aug 21;354(9179):617-2110466661
Cites: Eur Heart J. 2004 Nov;25(22):1990-715541834
Cites: Am J Cardiol. 2005 Aug 1;96(3):363-516054458
Cites: Diabet Med. 2005 Sep;22(9):1212-716108851
Cites: Clin Ther. 2005;27 Suppl B:S42-5616519037
Cites: Clin Physiol Funct Imaging. 2007 Jan;27(1):60-617204040
Cites: Circ J. 2007 Jun;71(6):834-4117526977
Cites: Circulation. 2007 Jul 10;116(2):151-717576864
Cites: Circulation. 2007 Nov 27;116(22):2634-5317951284
Cites: Heart Vessels. 2009 Mar;24(2):90-519337791
Cites: Prim Care Diabetes. 2009 Nov;3(4):205-919875348
Cites: Diabetes Care. 2010 Jan;33 Suppl 1:S62-920042775
Cites: Cardiovasc Diabetol. 2010;9:7521070650
Cites: Cardiovasc Diabetol. 2011;10:5621702911
Cites: Hypertension. 2000 Aug;36(2):245-910948085
PubMed ID
22873202 View in PubMed
Less detail

A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern.

https://arctichealth.org/en/permalink/ahliterature47352
Source
J Intern Med. 2003 Oct;254(4):386-90
Publication Type
Article
Date
Oct-2003
Author
R. Rosmond
S. Wallerius
P. Wanger
L. Martin
G. Holm
P. Björntorp
Author Affiliation
Cardiovascular Institute, Sahlgrenska University Hospital, Göteborg, Sweden.
Source
J Intern Med. 2003 Oct;254(4):386-90
Date
Oct-2003
Language
English
Publication Type
Article
Keywords
Angina Pectoris - epidemiology - metabolism
Biological Markers - blood
Blood pressure
Cardiovascular Diseases - epidemiology - metabolism
Cerebrovascular Accident - epidemiology - metabolism
Cohort Studies
Diabetes Mellitus, Type 2 - epidemiology - metabolism
Follow-Up Studies
Glucose - analysis
Humans
Hydrocortisone - analysis
Hypertension - epidemiology - metabolism
Incidence
Insulin - analysis
Male
Middle Aged
Myocardial Infarction - epidemiology - metabolism
Sweden - epidemiology
Testosterone - blood
Abstract
OBJECTIVES: Previous studies have suggested that abnormal levels of cortisol and testosterone might increase the risk of serious somatic diseases. To test this hypothesis, we conducted a 5-year follow-up study in middle-aged men. METHODS: A population-based cohort study conducted in 1995 amongst 141 Swedish men born in 1944, in whom a clinical examination supplemented by medical history aimed to disclose the presence of cardiovascular disease (CVD) (myocardial infarction, angina pectoris, stroke), type 2 diabetes and hypertension were performed at baseline and at follow-up in the year 2000. In addition, salivary cortisol levels were measured repeatedly over the day. Serum testosterone concentrations were also determined. Using the baseline data, an algorithm was constructed, which classified the secretion pattern of cortisol and testosterone from each individual as being normal or abnormal. RESULTS: By the end of follow-up, men with an abnormal hormone secretion pattern (n = 73) had elevated mean arterial pressure (P = 0.003), fasting insulin (P = 0.009) and insulin : glucose ratio (P = 0.005) compared with men with a normal secretion pattern (n = 68). Body mass index, waist circumference, and waist : hip ratio were significantly elevated in both groups. However, the 5-year incidence of CVD, type 2 diabetes, and hypertension were significantly higher (P
PubMed ID
12974877 View in PubMed
Less detail

18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.

https://arctichealth.org/en/permalink/ahliterature153281
Source
J Otolaryngol Head Neck Surg. 2008 Oct;37(5):712-7
Publication Type
Article
Date
Oct-2008
Author
Max Dahele
Yee C Ung
Lisa Ehrlich
Jay Silverberg
Judith Balogh
C Shun Wong
Author Affiliation
Departmentof Radiation Oncology, University of Toronto, Edmond Odette Cancer Centre,Toronto, Ontario.
Source
J Otolaryngol Head Neck Surg. 2008 Oct;37(5):712-7
Date
Oct-2008
Language
English
Publication Type
Article
Keywords
Adult
Aged
Biological Markers - blood
Cancer Care Facilities
Carcinoma, Papillary - pathology - radionuclide imaging - surgery
Cohort Studies
Female
Fluorodeoxyglucose F18 - diagnostic use
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local - pathology - radionuclide imaging - surgery
Neoplasm Staging
Ontario
Positron-Emission Tomography - methods
Reproducibility of Results
Retrospective Studies
Risk assessment
Sensitivity and specificity
Thyroglobulin - blood
Thyroid Neoplasms - pathology - radionuclide imaging - surgery
Thyroidectomy - methods
Time Factors
Treatment Outcome
Young Adult
Abstract
To report the initial experience with combined 18F-fluorodeoxyglucose positron emission tomography (FDG PET)/computed tomography (CT) imaging for suspected recurrent papillary differentiated thyroid cancer (DTC) at Sunnybrook Health Sciences Centre (SHSC), Toronto.
Single institution retrospective study.
Consecutive patients from SHSC who underwent FDG PET/CT imaging for suspected recurrent DTC over a period of 2.5 years were identified and their charts reviewed.
Qualitative appraisal of FDG PET/CT imaging in suspected recurrent DTC.
Sixteen patients (14F, 2M) were identified accounting for 17 FDG PET/CT scans. Three scans (18%) in 3 different patients were reported as suspicious for recurrent disease in the neck (1-3 lesions) and were considered "positive". All were subsequently confirmed pathologically (4-13 positive lymph nodes post operatively). Prior conventional imaging was abnormal in two patients. Two patients had an elevated non-stimulated thyroglobulin (TG)
PubMed ID
19128681 View in PubMed
Less detail

25-hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis.

https://arctichealth.org/en/permalink/ahliterature118271
Source
Ann Neurol. 2013 Jan;73(1):38-47
Publication Type
Article
Date
Jan-2013
Author
Peter Brøndum-Jacobsen
Børge G Nordestgaard
Peter Schnohr
Marianne Benn
Author Affiliation
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Denmark.
Source
Ann Neurol. 2013 Jan;73(1):38-47
Date
Jan-2013
Language
English
Publication Type
Article
Keywords
Aged
Biological Markers - blood
Brain Ischemia - blood - diagnosis - epidemiology
Denmark - epidemiology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Population Surveillance - methods
Prospective Studies
Risk factors
Stroke - blood - diagnosis - epidemiology
Vitamin D - analogs & derivatives - blood
Abstract
We tested the hypothesis that low plasma concentrations of 25-hydroxyvitamin D are associated with increased risk of symptomatic ischemic stroke in the general population.
We measured plasma 25-hydroxyvitamin D in 10,170 individuals from the general population, the Copenhagen City Heart Study. During 21 years of follow-up, 1,256 and 164 persons developed ischemic and hemorrhagic stroke, respectively. In a meta-analysis of ischemic stroke, we included 10 studies, 58,384 participants, and 2,644 events.
Stepwise decreasing plasma 25-hydroxyvitamin D concentrations were associated with stepwise increasing risk of ischemic stroke both as a function of seasonally adjusted percentile categories and as a function of clinical categories of 25-hydroxyvitamin D (p for trend = 2 × 10(-3)). In a Cox regression model comparing individuals with plasma 25-hydroxyvitamin D concentrations between the 1st and 4th percentiles to individuals with 25-hydroxyvitamin D concentrations between the 50th and 100th percentiles, multivariate adjusted hazard ratio of ischemic stroke was 1.82 (95% confidence interval, 1.41-2.34). Comparing individuals with clinical categories of severe vitamin D deficiency (
PubMed ID
23225498 View in PubMed
Less detail

25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18,791 participants.

https://arctichealth.org/en/permalink/ahliterature117634
Source
J Thromb Haemost. 2013 Mar;11(3):423-31
Publication Type
Article
Date
Mar-2013
Author
P. Brøndum-Jacobsen
M. Benn
A. Tybjaerg-Hansen
B G Nordestgaard
Author Affiliation
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark.
Source
J Thromb Haemost. 2013 Mar;11(3):423-31
Date
Mar-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Biological Markers - blood
Denmark
Down-Regulation
Female
Humans
Incidence
Kaplan-Meier Estimate
Linear Models
Male
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Prospective Studies
Risk assessment
Risk factors
Seasons
Time Factors
Venous Thromboembolism - blood - diagnosis - epidemiology
Vitamin D - analogs & derivatives - blood
Vitamin D Deficiency - blood - diagnosis - epidemiology
Abstract
Vitamin D has potential antithrombotic effects, suggesting that vitamin D analogs could be used as adjunctive antithrombotic agents. However, epidemiologic evidence of an association between reduced 25-hydroxyvitamin D concentrations and the risk of venous thromboembolism is lacking.
To test the hypothesis that reduced plasma 25-hydroxyvitamin D concentrations are associated with an increased risk of venous thromboembolism in the general population.
We prospectively studied 18 791 participants from the Copenhagen City Heart Study and the Copenhagen General Population Study. During up to 30 years of follow-up, 950 participants were diagnosed with venous thromboembolism. Plasma 25-hydroxyvitamin D concentrations were adjusted for seasonal variation.
The cumulative incidence of venous thromboembolism as a function of age increased with decreasing tertiles of seasonally adjusted plasma 25-hydroxyvitamin D (log-rank trend: P = 4 × 10(-4) ). On comparison of participants in the lowest and the highest tertile of plasma 25-hydroxyvitamin D concentrations, the crude risk estimate in a model adjusted for age and sex was a 37% (95% confidence interval [CI] 15-64%) increased risk of venous thromboembolism. The corresponding risk increase in a model adjusted for age, sex, body mass index, smoking and cancer was 26% (95% CI 5-51%), and in a multivariable-adjusted model also including physical activity, hormone replacement therapy, menopausal status, oral contraception use and lipid-lowering therapy it was 28% (95% CI 6-53%). Furthermore, corresponding risk increases with attempts to correct for regression dilution bias were 103% (95% CI 37-202%), 70% (95% CI 14-155%) and 73% (95% CI 15-160%) in the three models, respectively.
In these large general population studies, we observed a stepwise increasing risk of venous thromboembolism with decreasing tertiles of seasonally adjusted plasma 25-hydroxyvitamin D concentrations.
PubMed ID
23279309 View in PubMed
Less detail

25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies.

https://arctichealth.org/en/permalink/ahliterature121124
Source
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2794-802
Publication Type
Article
Date
Nov-2012
Author
Peter Brøndum-Jacobsen
Marianne Benn
Gorm B Jensen
Børge G Nordestgaard
Author Affiliation
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
Source
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2794-802
Date
Nov-2012
Language
English
Publication Type
Article
Keywords
Aged
Biological Markers - blood
Denmark - epidemiology
Female
Follow-Up Studies
Humans
Incidence
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction - blood - epidemiology - mortality
Myocardial Ischemia - blood - epidemiology - mortality
Prognosis
Proportional Hazards Models
Prospective Studies
Risk assessment
Risk factors
Time Factors
Vitamin D - analogs & derivatives - blood
Vitamin D Deficiency - blood - diagnosis - epidemiology - mortality
Abstract
We tested the hypothesis that reduced plasma 25-hydroxyvitamin D associates with increased risk of ischemic heart disease, myocardial infarction, and early death.
We measured baseline plasma 25-hydroxyvitamin D in 10 170 women and men from the Danish general population without vitamin D-fortified food. During 29 years of follow-up, 3100 persons developed ischemic heart disease, 1625 myocardial infarction, and 6747 died. Decreasing plasma 25-hydroxyvitamin D levels were associated with increasing risk of ischemic heart disease, myocardial infarction, and early death as a function of seasonally adjusted percentile categories (P for trend, 2×10(-4)-3×10(-53)). Comparing individuals with plasma 25-hydroxyvitamin D levels at the 1st to 4th percentile with individuals with levels at the 50th to 100th percentile, the multivariable adjusted risk was increased by 40% (95% CI, 14%-72%) for ischemic heart disease, by 64% (25%-114%) for myocardial infarction, by 57% (38%-78%) for early death, and by 81% (40%-135%) for fatal ischemic heart disease/myocardial infarction. In the meta-analyses of 18 and 17 studies, risk of ischemic heart disease and early death were increased by 39% (25%-54%) and 46% (31%-64%) for lowest versus highest quartile of 25-hydroxyvitamin D level.
We observed increasing risk of ischemic heart disease, myocardial infarction, and early death with decreasing plasma 25-hydroxyvitamin D levels. These findings were substantiated in meta-analyses.
PubMed ID
22936341 View in PubMed
Less detail

A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.

https://arctichealth.org/en/permalink/ahliterature145472
Source
J Hum Hypertens. 2010 Nov;24(11):739-48
Publication Type
Article
Date
Nov-2010
Author
N. Racine
P. Hamet
J S Sampalis
N. Longo
N. Bastien
Author Affiliation
Department of Medicine, Montreal Heart Institute, Montréal, Québec, Canada.
Source
J Hum Hypertens. 2010 Nov;24(11):739-48
Date
Nov-2010
Language
English
Publication Type
Article
Keywords
Adult
Aged
Angiotensin II Type 1 Receptor Blockers - adverse effects - therapeutic use
Antihypertensive Agents - adverse effects - therapeutic use
Biological Markers - blood
Blood Glucose - drug effects - metabolism
Blood Pressure - drug effects
Calcium Channel Blockers - therapeutic use
Canada
Chi-Square Distribution
Diabetes Mellitus - blood - chemically induced
Diuretics - adverse effects - therapeutic use
Drug Therapy, Combination
Female
Hemoglobin A, Glycosylated - metabolism
Humans
Hydrochlorothiazide - adverse effects - therapeutic use
Hypertension - blood - complications - drug therapy - physiopathology
Linear Models
Losartan - adverse effects - therapeutic use
Male
Metabolic Syndrome X - blood - complications - physiopathology
Middle Aged
Prospective Studies
Risk assessment
Risk factors
Time Factors
Treatment Outcome
Abstract
The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed. This was a 52-week multicentre, prospective, phase-IV, open-label, cohort study of losartan or losartan/HCTZ in hypertensive patients with metabolic syndrome. All subjects were treated initially with losartan 50?mg?day(-1). Those not achieving target blood pressure (BP
PubMed ID
20147971 View in PubMed
Less detail

450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy.

https://arctichealth.org/en/permalink/ahliterature122072
Source
Environ Health Perspect. 2012 Oct;120(10):1425-31
Publication Type
Article
Date
Oct-2012
Author
Bonnie R Joubert
Siri E Håberg
Roy M Nilsen
Xuting Wang
Stein E Vollset
Susan K Murphy
Zhiqing Huang
Cathrine Hoyo
Øivind Midttun
Lea A Cupul-Uicab
Per M Ueland
Michael C Wu
Wenche Nystad
Douglas A Bell
Shyamal D Peddada
Stephanie J London
Author Affiliation
Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina 27709, USA.
Source
Environ Health Perspect. 2012 Oct;120(10):1425-31
Date
Oct-2012
Language
English
Publication Type
Article
Keywords
Adult
Basic Helix-Loop-Helix Transcription Factors - genetics - metabolism
Biological Markers - blood
Chromatography, Liquid
Cohort Studies
Cotinine - blood
Cytochrome P-450 CYP1A1 - genetics - metabolism
DNA Methylation
DNA-Binding Proteins - genetics - metabolism
Epigenesis, Genetic
Female
Fetal Blood
Genome-Wide Association Study
Humans
Infant, Newborn
Male
Maternal Exposure
Norway - epidemiology
Pregnancy
Prenatal Exposure Delayed Effects - chemically induced - epidemiology - genetics
Repressor Proteins - genetics - metabolism
Tandem Mass Spectrometry
Tobacco Smoke Pollution - adverse effects
Transcription Factors - genetics - metabolism
United States - epidemiology
Abstract
Epigenetic modifications, such as DNA methylation, due to in utero exposures may play a critical role in early programming for childhood and adult illness. Maternal smoking is a major risk factor for multiple adverse health outcomes in children, but the underlying mechanisms are unclear.
We investigated epigenome-wide methylation in cord blood of newborns in relation to maternal smoking during pregnancy.
We examined maternal plasma cotinine (an objective biomarker of smoking) measured during pregnancy in relation to DNA methylation at 473,844 CpG sites (CpGs) in 1,062 newborn cord blood samples from the Norwegian Mother and Child Cohort Study (MoBa) using the Infinium HumanMethylation450 BeadChip (450K).
We found differential DNA methylation at epigenome-wide statistical significance (p-value
Notes
Cites: Hum Mol Genet. 2012 Jul 1;21(13):3073-8222492999
Cites: Epigenetics. 2011 Nov;6(11):1284-9421937876
Cites: Mol Cell Biol. 2004 Oct;24(20):8803-1215456856
Cites: Genome Biol. 2004;5(10):R8015461798
Cites: Mol Cell Biol. 2005 Dec;25(23):10338-5116287849
Cites: Biochem Pharmacol. 2006 Jul 28;72(3):267-7916488401
Cites: Eur J Epidemiol. 2006;21(8):619-2517031521
Cites: Int J Epidemiol. 2006 Oct;35(5):1146-5016926217
Cites: Nature. 2007 May 24;447(7143):425-3217522676
Cites: Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13056-6117670942
Cites: Arch Biochem Biophys. 2007 Aug 15;464(2):207-1217481570
Cites: Chem Res Toxicol. 2008 Jan;21(1):102-1618076143
Cites: Pediatr Res. 2008 Jun;63(6):593-818317238
Cites: Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2306-1018768498
Cites: J Clin Invest. 2008 Oct;118(10):3462-918802477
Cites: J Pediatr. 2009 Jan;154(1):17-918990410
Cites: Rapid Commun Mass Spectrom. 2009 May;23(9):1371-919337982
Cites: Genome Res. 2009 Jul;19(7):1165-7419494038
Cites: Am J Respir Crit Care Med. 2009 Sep 1;180(5):462-719498054
Cites: J Cell Physiol. 2010 Feb;222(2):282-519847803
Cites: Virchows Arch. 2010 Jan;456(1):13-2119844740
Cites: Science. 2010 Sep 10;329(5997):1345-820688981
Cites: J Allergy Clin Immunol. 2011 Jan;127(1):262-4, 264.e121094522
Cites: Am J Epidemiol. 2011 Feb 1;173(3):355-921178103
Cites: BMC Public Health. 2011;11(1):4621255390
Cites: Am J Hum Genet. 2011 Apr 8;88(4):450-721457905
Cites: Blood. 2011 Apr 14;117(15):e142-5021343615
Cites: Epigenetics. 2011 Jun;6(6):692-70221593595
Cites: Stem Cells. 2011 Feb;29(2):376-8521732494
Cites: Nat Rev Genet. 2011 Aug;12(8):529-4121747404
Cites: Genomics. 2011 Oct;98(4):288-9521839163
Cites: Semin Immunol. 2011 Oct;23(5):368-7821920773
Cites: J Biol Chem. 2011 Dec 16;286(50):43214-2821984831
Cites: Am J Med Genet B Neuropsychiatr Genet. 2012 Mar;159B(2):141-5122232023
Cites: Nat Immunol. 2012 Feb;13(2):117-922261961
Cites: Gene. 2012 Feb 15;494(1):36-4322202639
Cites: Environ Health Perspect. 2012 Feb;120(2):296-30222005006
Cites: Environ Health Perspect. 2012 Mar;120(3):355-6022128036
Comment In: Environ Health Perspect. 2012 Oct;120(10):a40223026408
Erratum In: Environ Health Perspect. 2012 Dec;120(12):A455
PubMed ID
22851337 View in PubMed
Less detail

A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes.

https://arctichealth.org/en/permalink/ahliterature149324
Source
Diabetes. 2009 Nov;58(11):2649-55
Publication Type
Article
Date
Nov-2009
Author
Johan Wadén
Carol Forsblom
Lena M Thorn
Daniel Gordin
Markku Saraheimo
Per-Henrik Groop
Author Affiliation
Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland. per-henrik.groop@helsinki.fi
Source
Diabetes. 2009 Nov;58(11):2649-55
Date
Nov-2009
Language
English
Publication Type
Article
Keywords
Adult
Albuminuria - epidemiology
Autoanalysis - methods
Biological Markers - blood
Blood pressure
Cardiovascular Diseases - epidemiology - mortality
Diabetes Mellitus, Type 1 - blood
Diabetic Angiopathies - epidemiology - mortality
Diabetic Nephropathies - epidemiology - mortality
Female
Finland - epidemiology
Follow-Up Studies
Glucose - metabolism
Hemoglobin A, Glycosylated - metabolism
Humans
Kidney Failure, Chronic - epidemiology
Lipids - blood
Male
Middle Aged
Patient Selection
Predictive value of tests
Risk factors
Survival Rate
Abstract
Recent data from the Diabetes Control and Complications Trial (DCCT) indicated that A1C variability is associated with the risk of diabetes microvascular complications. However, these results might have been influenced by the interventional study design. Therefore, we investigated the longitudinal associations between A1C variability and diabetes complications in patients with type 1 diabetes in the observational Finnish Diabetic Nephropathy (FinnDiane) Study.
A total of 2,107 patients in the FinnDiane Study had complete data on renal status and serial measurements of A1C from baseline to follow-up (median 5.7 years), and 1,845 patients had similar data on cardiovascular disease (CVD) events. Intrapersonal SD of serially measured A1C was considered a measure of variability.
During follow-up, 10.2% progressed to a higher albuminuria level or to end-stage renal disease, whereas 8.6% had a CVD event. The SD of serial A1C was 1.01 versus 0.75 (P
Notes
Cites: N Engl J Med. 2005 Dec 22;353(25):2643-5316371630
Cites: Scand J Clin Lab Invest. 2005;65(6):453-6216179278
Cites: Diabetes Care. 2006 Jul;29(7):1486-9016801566
Cites: Am Heart J. 2006 Jul;152(1):27-3816824829
Cites: Nat Clin Pract Endocrinol Metab. 2005 Dec;1(2):100-1016929378
Cites: Diabetologia. 2007 Nov;50(11):2280-817768606
Cites: Diabetologia. 2008 Jan;51(1):183-9017994218
Cites: Diabetes Care. 2008 Feb;31(2):230-217959867
Cites: Diabetes. 2008 May;57(5):1349-5418299315
Cites: Diabetes Care. 2008 Nov;31(11):2198-20218650371
Cites: Diabetes Care. 2009 Jan;32(1):187-9219092168
Cites: Diabetes Care. 2009 Sep;32(9):1689-9319502539
Cites: N Engl J Med. 1993 Sep 30;329(14):977-868366922
Cites: Br J Ophthalmol. 1998 Jul;82(7):725-309924360
Cites: Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):1014-910195930
Cites: Diabetologia. 1999 Sep;42(9):1113-910447524
Cites: Am J Physiol Endocrinol Metab. 2001 Nov;281(5):E924-3011595647
Cites: Diabetes Care. 2000 Jan;23(1):45-5010857967
Cites: Diabetes Care. 2005 Apr;28(4):777-8215793172
Cites: Nature. 2001 Dec 13;414(6865):813-2011742414
Cites: J Clin Invest. 2002 Mar;109(6):805-1511901189
Cites: J Diabetes Complications. 2003 Mar-Apr;17(2):78-8112614973
Cites: Diabetes Care. 2003 May;26(5):1374-912716791
Cites: Diabetes. 2003 Nov;52(11):2795-80414578299
Cites: Diabetes Care. 2004 Feb;27(2):530-714747240
Cites: Am J Physiol Renal Physiol. 2004 Aug;287(2):F268-7315113747
Cites: Ann Intern Med. 2004 Sep 21;141(6):421-3115381515
Cites: Arch Intern Med. 2004 Sep 27;164(17):1917-2415451768
Cites: Lancet. 1982 Jan 16;1(8264):121-46119509
Cites: Br Med J (Clin Res Ed). 1986 Nov 8;293(6556):1195-93096429
Cites: N Engl J Med. 1993 Jul 29;329(5):304-98147960
Cites: Arch Intern Med. 1994 Nov 14;154(21):2473-97979844
Cites: BMJ. 1996 Sep 28;313(7060):779-848842069
Cites: Arch Ophthalmol. 1998 Jul;116(7):874-869682700
Cites: Diabetologia. 1998 Jul;41(7):784-909686919
Cites: Diabetes Care. 2005 Aug;28(8):2019-2416043748
Cites: JAMA. 2006 Apr 12;295(14):1681-716609090
PubMed ID
19651819 View in PubMed
Less detail

1530 records – page 1 of 153.